Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Roper

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Medicinal Chemistry|April 29, 2026
An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 InhibitorFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Haematologica|March 5, 2026
GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa studyRichard F Schlenk, Claire N Harrison, Francesca Palandri, et al.
Journal of Medicinal Chemistry|September 26, 2022
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic DiseaseFredrik R Zetterberg, Alison MacKinnon, Thomas Brimert, et al.
Journal of Medicinal Chemistry|October 17, 2024
Core Modifications of GSK3335103 toward Orally Bioavailable α<sub>v</sub>β<sub>6</sub> Inhibitors with Improved Synthetic TractabilityHeather F Hryczanek, John Barrett, Tim N Barrett, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung CancerFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Journal of Medicinal Chemistry|August 6, 2019
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective MethylationTim N Barrett, Jonathan A Taylor, Daniel Barker, et al.
European Journal of Pharmacology|November 11, 2021
Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic diseaseAlex L Wilkinson, Alison E John, John W Barrett, et al.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Medicinal Chemistry|April 29, 2026
An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 InhibitorFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Haematologica|March 5, 2026
GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa studyRichard F Schlenk, Claire N Harrison, Francesca Palandri, et al.
Journal of Medicinal Chemistry|September 26, 2022
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic DiseaseFredrik R Zetterberg, Alison MacKinnon, Thomas Brimert, et al.
Journal of Medicinal Chemistry|October 17, 2024
Core Modifications of GSK3335103 toward Orally Bioavailable α<sub>v</sub>β<sub>6</sub> Inhibitors with Improved Synthetic TractabilityHeather F Hryczanek, John Barrett, Tim N Barrett, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung CancerFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Journal of Medicinal Chemistry|August 6, 2019
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective MethylationTim N Barrett, Jonathan A Taylor, Daniel Barker, et al.
European Journal of Pharmacology|November 11, 2021
Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic diseaseAlex L Wilkinson, Alison E John, John W Barrett, et al.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
Pageof 3